RxDoctor Payments Data

Sudeshna Nandi, MD

Geriatric Medicine · Duluth, GANPI 1487671319

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.

$5,904in general payments, 2019–2025

Across 254 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$871
  • Lilly USA, LLC$660
  • AbbVie$364
  • Amgen$264
  • Astellas Pharma US Inc$259
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$5,85499%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,904 in reported general payments places this provider in the 85th percentile of 75 geriatric medicine providers in Georgia.

See all geriatric medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$64,529
Medicare patients
190
Services billed
1,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$23,149
JanuviaSitagliptin Phosphate14$13,395
FarxigaDapagliflozin Propanediol17$9,823
Repatha SureclickEvolocumab11$6,075
ArexvyRsvpref3 Antigen/As01e/Pf18$5,566
Fentanyl12$3,878
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,377
Levothyroxine Sodium101$1,074
Gabapentin52$1,025
Morphine Sulfate11$916
Boostrix TdapDiphth,pertuss(Acell),tet Vac13$891
Omeprazole58$625
Fenofibrate34$588
Albuterol Sulfate HfaAlbuterol Sulfate21$512
Atorvastatin Calcium100$511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,146$23,14927 claims
MerckJanuvia$141$13,39514 claims
AstraZenecaFarxiga$871$9,82317 claims
GSKArexvy, Shingrix$259$7,94329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 75 geriatric medicine providers in Georgia.

Other geriatric medicine in Duluth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →